Us Fda Approves Vertexs Kalydeco To Treat Eligible Infants With Cf Ages 1 Month And Older
Vertex Pharmaceuticals Incorporated Announced The Us Food And Drug Administration (Fda) Approved Kalydeco (Ivacaftor) For Use In Children With Cystic Fibrosis (Cf) Ages 1 Month To Less Than Four Months Old Who Have At Least One Mutation In Their Cystic Fibrosis Transmembrane Conductance Regulator (Cftr) Gene That Is Responsive To Kalydeco Based On Clinical And/Or In Vitro Assay Data.Kalydeco Is Already Approved In The Us And Eu For The Treatment Of Cf In Patients Ages Four Months And Older.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
